Insider · CIK 0001779990
Michael Thomas Henderson
ceoofficerdirector
Files at SYRE (Spyre Therapeutics, Inc.), APGE (Apogee Therapeutics, Inc.). First filing Nov 8, 2024, latest Mar 7, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $3.2M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Apogee Therapeutics, Inc. | $302k 10,000 shares | -1% | - | |
| 33Weak | Apogee Therapeutics, Inc. | $609k 15,000 shares | -1% | - | |
| 34Weak | Apogee Therapeutics, Inc. | $733k 15,000 shares | -1% | - | |
| 34Weak | Apogee Therapeutics, Inc. | $699k 15,000 shares | -1% | - | |
| 36Weak | Apogee Therapeutics, Inc. | $888k 15,000 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Common Stock | -920,941 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -387,012 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -357,036 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -253,016 | - | - | 0 | 39 d ago |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| Mar 5, 2025 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,326 | $29.98 | $220k | 1,295,661 | Mar 7, 2025 |
| Mar 5, 2025 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,674 | $30.62 | $82k | 1,292,987 | Mar 7, 2025 |
| Feb 5, 2025 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $40.58 | $609k | 1,302,987 | Feb 7, 2025 |
| Jan 31, 2025 | APGE Apogee Therapeutics, Inc. | MOption exercise Common Stock | +8,500 | $22.86 | $194k | 1,317,987 | Jan 31, 2025 |
| Jan 31, 2025 | APGE Apogee Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -8,500 | $0.00 | $0 | 390,012 | Jan 31, 2025 |
| Jan 10, 2025 | SYRE Spyre Therapeutics, Inc. | JOther Common Stock | +105,379 | $0.00 | $0 | 105,379 | Jan 14, 2025 |
| Jan 8, 2025 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -12,132 | $48.72 | $591k | 1,312,355 | Jan 10, 2025 |
| Jan 8, 2025 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,868 | $49.38 | $142k | 1,309,487 | Jan 10, 2025 |
| Dec 9, 2024 | APGE Apogee Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +357,036 | $0.00 | $0 | 357,036 | Dec 11, 2024 |
| Dec 4, 2024 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -13,328 | $46.50 | $620k | 1,326,159 | Dec 6, 2024 |
| Dec 4, 2024 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,672 | $47.19 | $79k | 1,324,487 | Dec 6, 2024 |
| Nov 6, 2024 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -14,000 | $59.17 | $828k | 1,340,487 | Nov 8, 2024 |
| Nov 6, 2024 | APGE Apogee Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,000 | $59.94 | $60k | 1,339,487 | Nov 8, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.